High Prevalence of Heart Failure Leads to Various Clinical Trials Focusing On R&D of Effective Congestive Heart Failure Drugs
Congestive Heart Failure Drugs include beta blockers (carvedilol, metoprolol, bisoprilol), ACE inhibitors (lisinopril, captopril), angiotensin receptor blockers (losartan), combination medicines (Entresto, or sacubitril/valsartan), aldosterone antagonist (spironolactone, eplerenone), digoxin (Lanoxin), and others.
High prevalence of heart failure has led to various clinical trials focusing on R&D of Congestive Heart Failure Drugs. For instance, in November 2020, a clinical trial by Brigham and Women's Hospital and sponsored by Lexicon Pharmaceuticals, a biopharmaceutical company based in the U.S., reported that sotagliflozin, a combination sodium/glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo.
ACE inhibitors are the most commonly used Congestive Heart Failure Drugs. They lower the heart rate and blood pressure, thereby reducing the number of heart attacks. However, there are a few negative side effects attached to using these medicines. Some patients suffer from renal failure, while some experience chest pain and dizziness. These medicines are also known to cause sexual dysfunction in some patients.
Comments
Post a Comment